Two CEOs. Two industries. One search that keeps popping up. Miguel Patricio and Albert Bourla are not business partners or relatives: Patricio is the former Kraft Heinz CEO and Executive Chair now on the AB InBev board, while Bourla is Pfizer’s Chairman and CEO, who turned 65 on October 21, 2026. So why do people search for them together? This guide gives you their real careers, pay figures and latest news, without the internet myths.
Quick Facts About Miguel Patricio and Albert Bourla
- Miguel Patricio became CEO of Kraft Heinz on July 1, 2019. AB InBev lists his CEO years as 2019 to 2023, and Carlos Abrams Rivera took over on January 1, 2024.
- Patricio served as Kraft Heinz Chair from May 2022 to December 2025, according to AB InBev. Kraft Heinz’s 2026 proxy statement thanks him as its retiring Executive Chair.
- Albert Bourla has been Pfizer’s CEO since January 2019 and its Chairman since January 2020.
- Bourla was born on October 21, 1961, in Thessaloniki, Greece. Patricio is Portuguese and is roughly 60 years old, although his exact birthdate is not public.
- Pfizer’s proxy statement reports Bourla’s 2025 total compensation at $27,585,301. No filing reports a net worth for either man, and online estimates are unsourced.
- Kraft Heinz now has a new CEO, Steve Cahillane, and paused its planned split in February 2026. Pfizer reported 2025 revenue of $62.6 billion.
Miguel Patricio vs Albert Bourla at a Glance
| Detail | Miguel Patricio | Albert Bourla |
| Born | Portugal, mid 1960s (exact date not public) | October 21, 1961, Thessaloniki, Greece |
| Age on October 22, 2026 | About 60 | 65 |
| Nationality | Portuguese | Greek born, American citizen |
| Education | Business Administration, Fundação Getulio Vargas, São Paulo | Doctor of Veterinary Medicine and PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki |
| Industry | Consumer goods, beverages, packaged food | Pharmaceuticals and biotechnology |
| Main company | Kraft Heinz | Pfizer |
| CEO start date | July 1, 2019 | January 1, 2019 |
| Role in 2026 | Retired Kraft Heinz Executive Chair, AB InBev board member | Chairman and CEO of Pfizer |
| Earlier career | Philip Morris, Coca Cola, Johnson & Johnson, Ambev, AB InBev | Pfizer since 1993, starting in animal health |
| Latest verified pay | Not confirmed in the filings checked | $27,585,301 total compensation for 2025 |
Are Miguel Patricio and Albert Bourla Connected?
Short answer: no. Company filings, official biographies and news archives do not record a partnership, a shared board seat, a joint deal or a family tie between the two men.
Are They Business Partners?
No. Their companies do not overlap. Kraft Heinz sells food brands such as Heinz, Philadelphia and Oscar Mayer, while Pfizer develops and sells medicines and vaccines. Pfizer’s 2026 proxy statement lists twelve director nominees, and Patricio is not one of them. Pages that hint at a business relationship between the two rarely show a filing or press release to support it.
Are They Related?
Nothing in public records points to a family relationship. Patricio is Portuguese and built his career at Ambev and AB InBev after studying in São Paulo. Bourla was born in Greece and spent more than three decades at Pfizer.
Why Do Their Names Appear Together?
The overlap comes down to timing and status. Bourla became Pfizer’s CEO on January 1, 2019. Kraft Heinz announced Patricio as its next CEO in April 2019, and he started on July 1. Both later held the chair role at their companies.
Search suggestions, list articles and data sites tend to group executives like this, which is the most likely reason the two names travel together online. That is an inference, not a documented link.
Must Read: Hiroshi Mikitani and James Gorman: The Untold Connection 2026
Who Is Miguel Patricio?
Nationality, Education and Early Career
Patricio is a Portuguese citizen with a degree in Business Administration from Fundação Getulio Vargas in São Paulo. Before joining Ambev in 1998, he held senior positions across the Americas at consumer product companies. Public profiles name Philip Morris, Coca-Cola and Johnson & Johnson among his earlier employers.
From Ambev to Global Marketing Chief at AB InBev
At Ambev, Patricio was Chief Marketing Officer from 1999 to 2004. AB InBev’s own board profile then lists him as Zone President for North America from 2004 to 2007, Zone President for Asia Pacific from 2008 to 2012, and Chief Marketing Officer from 2012 to 2018.
Some news reports give slightly different North America dates, so the company profile is the safer source. When Kraft Heinz announced him as CEO, the company credited him with leading the turnaround of AB InBev’s China business and described him as a brand builder with a consumer-first approach.
Patricio as Kraft Heinz CEO, 2019 to 2023
Kraft Heinz announced Patricio’s appointment in April 2019, and he took over from Bernardo Hees on July 1, 2019. The timing was difficult. Two months earlier, the company had cut its dividend, written down the value of its Kraft and Oscar Mayer brands by about $15.4 billion and disclosed an SEC subpoena.
Patricio’s plan leaned on marketing and innovation. He worked to refresh brands such as Oscar Mayer and Maxwell House, aimed products at younger consumers and pushed into away-from-home sales with ideas such as customizable sauce dispensers for restaurants.
By 2023, demand had weakened, which reporters linked to higher prices and heavier promotions from competitors. Kraft Heinz announced in August 2023 that Carlos Abrams Rivera, then head of its North American business, would become CEO on January 1, 2024.
Chair, Executive Chair and Exit from Kraft Heinz Leadership
AB InBev’s profile says Patricio served as Kraft Heinz Chair from May 2022 to December 2025. In the 2026 proxy statement, new Chair John Cahill thanked him as the company’s retiring Executive Chair and credits his service as CEO, as a director and most recently as Executive Chair. Cahill became independent Chair on January 1, 2026.
Sources differ slightly on one point. AB InBev’s profile still calls Patricio a Kraft Heinz board member, while Kraft Heinz’s proxy letter focuses on his retirement as Executive Chair. Readers who need his exact board status should check Kraft Heinz’s latest SEC filing.
Patricio’s Role in 2026
AB InBev lists Patricio on its board as a representative of the main shareholders, nominated by BRC S.à.R.L., the holder of the class B Stichting certificates. A market data provider dates his AB InBev director listing to April 28, 2026. That makes AB InBev, rather than Kraft Heinz, his most visible corporate role today.
Kraft Heinz After Patricio: The Reset
The company Patricio left behind moved fast. Kraft Heinz announced a plan in September 2025 to split into two public companies, then named Steve Cahillane, the former Kellogg chief, as CEO from January 1, 2026.
On February 11, 2026, with a net loss near $6 billion and more than $6 billion of goodwill impairments on the books, Cahillane paused the split and committed $600 million to marketing, sales, research and product quality.
Kraft Heinz’s own proxy letter calls 2025 a disappointing year and admits execution fell short in U.S. retail. For Patricio’s legacy, that is the honest context: the company he led entered 2026 under new leadership and a reset strategy.
Who Is Albert Bourla?
Early Life and Family Background
Albert Bourla was born on October 21, 1961, in Thessaloniki, Greece, into the city’s Sephardic Jewish community. His parents were among roughly 2,000 of about 50,000 Jews in Thessaloniki who survived the Holocaust.
He has described how his mother escaped a firing squad during the Nazi occupation and how his father survived by pretending to be Christian. In a 2026 CNN interview, he said this history taught him and his sister that life is miraculous and that things are rarely as impossible as they seem.
He moved to the United States in 2001 after a promotion and later became a U.S. citizen. He sums up his identity as Greek by birth and American by choice.
Education: Veterinary Medicine and a PhD
Bourla studied at the Veterinary School of Aristotle University of Thessaloniki, where he earned a Doctor of Veterinary Medicine and a PhD in the biotechnology of reproduction. It is an unusual background for a pharmaceutical chief executive, and Pfizer’s own proxy statement cites his medicine and science training as part of what he brings to the board.
Career at Pfizer, from 1993 to CEO
Bourla joined Pfizer in 1993 in the animal health division as Technical Director of Greece. Pfizer’s proxy statement says his roles later spanned five countries and eight cities. The main steps were:
- President and General Manager of the Established Products business, 2010 to 2013.
- Responsibility for vaccines, oncology and consumer healthcare from 2014.
- Group President of Pfizer Innovative Health, June 2016 to December 2017.
- Chief Operating Officer, January to December 2018.
- Chief Executive Officer from January 2019 and Chairman from January 2020.
Leading Pfizer Through COVID
Bourla became a global name when Pfizer and BioNTech delivered a COVID vaccine in about eight months, followed by the first FDA-authorized oral antiviral treatment. Fortune reports that the vaccine nearly doubled Pfizer’s revenue to around $81.3 billion in 2021.
The reversal was just as sharp. In May 2026, Bourla said COVID revenue had fallen from $56 billion in 2022 to about $6 billion, a swing he said hurt internal confidence, although he credited a resilience culture for the recovery.
Pfizer’s Strategy After COVID
Bourla has rebuilt the pipeline through deals. He says Pfizer has invested more than $80 billion in acquisitions, including Seagen for roughly $40 billion, and Fortune reports that over 40 percent of R&D now goes to oncology.
Obesity is the second bet: Pfizer closed its Metsera acquisition in November 2025 after a bidding war with Novo Nordisk, at $65.60 per share in cash plus a contingent right worth up to $20.65.
The numbers explain the urgency. Pfizer reported 2025 revenue of $62.6 billion, down from $63.6 billion, with 2026 guidance of $59.5 billion to $62.5 billion. Its 2026 priorities are to maximize key deals, hit R&D milestones, invest for growth after 2028 and scale AI. In 2025, it also signed a voluntary pricing agreement with the U.S. government that came with a three-year grace period from certain tariffs.
Albert Bourla in 2026: Latest News
January: At the J.P. Morgan healthcare conference, he laid out the four priorities above and described 2026 as a catalyst-rich year.
March 2: He told a TD Cowen conference that Pfizer “has a problem” with the FDA’s vaccine chief, Vinay Prasad, saying Prasad was not following his staff’s advice, while describing working ties with FDA scientists as productive.
April 23: Pfizer’s annual meeting materials included a shareholder proposal asking the company to adopt an independent chair policy. Pfizer’s independent directors had decided in December 2025 that Bourla should stay Chairman in 2026.
May 20: In an interview on the program In Good Company, he warned that China could overtake the United States in early-stage drug discovery within one to two years.
June: He gave CNBC interviews on Pfizer’s obesity pipeline and oncology focus, and spoke at the CNBC CEO Council Summit.
October 9: He said he was disappointed by the pace of change from generative AI two years after its arrival, even though it has streamlined some business processes.
Awards and Recognition
- 2026: Elected to the American Academy of Arts and Sciences
- 2022: Genesis Prize for his pandemic leadership
- 2021: CNN Business CEO of the Year
- 2021: Named among Business Insider’s most transformative CEOs
- 2020: Ranked America’s top pharmaceutical CEO by Institutional Investor
- Ongoing: Listed on Fortune’s most powerful people in business and Time’s most influential people in health
Must Read: Satya Nadella and Michel Vounatsos: The Verified Link (2026)
Career Comparison: Brand Builder vs Science-Led CEO
Education and Path to CEO
Patricio studied business administration and rose through marketing, moving between several employers before a long run at Ambev and AB InBev. Bourla studied veterinary science, joined one company in 1993 and climbed inside it for more than three decades. Patricio arrived at Kraft Heinz as an outsider with a brand background. Bourla became Pfizer’s CEO after serving as its operating chief.
Industry and Leadership Challenges
A food company lives on shelf space, pricing, volume and brand relevance. Kraft Heinz’s recent troubles, including large brand write-downs and weak U.S. retail execution, reflect that world. A drug company lives on research success, patents, regulators and politics. Pfizer’s challenges include the post-COVID revenue drop, patent expirations, drug pricing pressure, FDA tensions and a late entry into the obesity race.
Leadership During Change
Patricio handed over the CEO role in 2024, left the chair role at the end of 2025 and watched the company reverse its split plan within months. Bourla remains both CEO and Chairman, and Pfizer’s independent directors decided in December 2025 that he should keep both roles in 2026. Pfizer’s own proxy statement also shows pressure: only 54.7 percent of shareholders backed executive pay in the 2025 advisory vote, far below the 93.5 percent average of 2015 to 2024.
Net Worth and Pay: What Can Actually Be Verified
Albert Bourla’s Pfizer Compensation, 2022 to 2025
| Year | Total compensation | Note |
| 2022 | $33,017,453 | Summary Compensation Table |
| 2023 | $21,562,064 | Summary Compensation Table |
| 2024 | $24,648,727 | 269 times the median employee, base salary $1,800,000 |
| 2025 | $27,585,301 | 277 times the median employee |
These figures come from Pfizer’s proxy statements. Compensation is what a company reports paying an executive in a year, including stock and option awards valued at grant. It is not the same as net worth.
Pfizer’s proxy also reports a total shareholder return of 0.7 percent for 2025, a loss of 42.2 percent over three years and a loss of 13.6 percent over five years, which helps explain why pay drew shareholder attention.
Miguel Patricio’s Disclosed Kraft Heinz Holdings
A market data provider estimates that Patricio held 1,286,794 Kraft Heinz shares, about 0.11 percent of the company, as of February 28, 2026, worth roughly $30 million at the end of June 2026. Treat that as an approximate third-party estimate for one company only. It is not a net worth, and you should confirm it in Kraft Heinz’s SEC filings.
Why Online Net Worth Figures Don’t Agree
Search for Bourla’s net worth, and you will find numbers from about $15 million to $150 million, including one page that attributes $77 million to Forbes. None of the pages we checked show a filing or method; several are labeled 2023, and one even confused Pfizer with Moderna. Pay is not wealth, stock prices move daily, and private assets are not disclosed, so a single precise number is almost always a guess.
Who Is Richer?
No reliable public source can settle it. What can be compared is disclosed pay for Bourla and an estimated Kraft Heinz holding for Patricio, and those measure different things. Anyone who names a winner is guessing.
To check the numbers yourself, take three steps:
- Open the latest proxy statement for Pfizer or Kraft Heinz on SEC EDGAR and read the Summary Compensation Table.
- Read the securities ownership table in the same document.
- Search Form 4 filings for recent insider purchases and sales.
Age, Birthplace and Heritage: Who Is Older?
Bourla turned 65 on October 21, 2026. Pfizer’s proxy listed his age as 64 as of its April 23, 2026 annual meeting, which matches that birthday. Patricio’s exact birthdate has not been published. Wikipedia gives 1966 or 1967, a data provider lists 59, and a 2023 news report gave his age as 57 in August 2023, which points to about 60 today. Bourla is therefore older by roughly four to six years.
Both were in their fifties when they became CEOs. Bourla was 57 in January 2019, and Patricio was in his early fifties in July 2019. Bourla is Greek-born, from a Sephardic Jewish family, and holds U.S. citizenship. Patricio is a native of Portugal.
Timeline: Miguel Patricio and Albert Bourla, 1993 to 2026
| Year | Event |
| 1993 | Bourla joins Pfizer’s animal health division in Greece |
| 1998 | Patricio joins Ambev |
| 1999 to 2004 | Patricio is Ambev’s Chief Marketing Officer |
| 2004 to 2007 | Patricio is AB InBev Zone President, North America |
| 2008 to 2012 | Patricio is Zone President, Asia Pacific |
| 2012 to 2018 | Patricio is AB InBev’s global Chief Marketing Officer |
| 2018 | Bourla becomes Pfizer’s Chief Operating Officer |
| January 2019 | Bourla becomes Pfizer CEO |
| July 1, 2019 | Patricio becomes Kraft Heinz CEO |
| January 2020 | Bourla also becomes Pfizer Chairman |
| May 2022 | Patricio becomes Kraft Heinz Chair |
| January 1, 2024 | Carlos Abrams Rivera succeeds Patricio as CEO |
| September 2025 | Kraft Heinz announces plan to split in two |
| November 2025 | Pfizer completes the Metsera acquisition |
| December 2025 | Kraft Heinz names Steve Cahillane CEO; Patricio’s Chair role ends |
| January 1, 2026 | Cahillane becomes CEO; John Cahill becomes independent Chair |
| February 11, 2026 | Kraft Heinz pauses the split and announces a $600 million investment |
| October 21, 2026 | Bourla turns 65 |
Common Mistakes and Outdated Claims About Them
- Calling Carlos Abrams Rivera the current Kraft Heinz CEO. He held the job from January 2024 to January 2026. Steve Cahillane has been CEO since January 1, 2026.
- Describing Patricio as the current Kraft Heinz CEO or Chair. He retired as Executive Chair, and John Cahill is independent Chair.
- Giving the wrong CEO years. One widely read profile lists 2019 to 2020, and others stretch it to 2024. AB InBev’s own profile says 2019 to 2023.
- Saying Bourla started at Pfizer as a quality control chemist. Pfizer’s biography says he joined as Technical Director of Greece in animal health.
- Rounding Pfizer’s 2025 revenue to $62.5 billion. The reported figure is $62.6 billion.
- Calling Metsera a flat $10 billion deal. The cash price was $65.60 per share, with a contingent payment of up to $20.65 per share on top.
- Quoting a precise net worth for either man without a filing behind it.
- Listing Bourla as 64 after October 21, 2026.
- Presenting the two as partners or relatives.
- Describing Pfizer’s 2025 pricing agreement with the U.S. government as a Medicaid-specific deal. Pfizer’s proxy statement calls it a voluntary agreement to make certain drug prices for U.S. patients more comparable with those in other developed countries, with a three-year grace period from certain tariffs. The Medicaid detail added by some pages was not confirmed in the sources checked.
Must Read: Travis Kalanick and Helen Mirren: Are They Connected? (2026)
What Comes Next for Each
For Bourla, 2026 is a delivery year. Pfizer plans about 20 key pivotal study starts, an expanded obesity program built on Metsera, continued oncology investment and more use of AI, all while absorbing patent expirations and political pressure on drug pricing. Pfizer’s independent directors have kept him in both top roles for 2026.
For Patricio, the story shifts from running Kraft Heinz to sitting on the AB InBev board as a shareholder representative. Kraft Heinz’s own next chapter now belongs to Cahillane, whose stated priority is returning the business to profitable growth.
Conclusion
Miguel Patricio and Albert Bourla share a timeline, not a business relationship. Both became CEOs in 2019, but they came from different worlds: marketing and consumer brands on one side, veterinary science and pharmaceuticals on the other. Patricio has moved from running Kraft Heinz to sitting on the AB InBev board. Bourla still runs Pfizer, now 65, and is betting on cancer and obesity medicines to carry the company past its patent cliff.
If you remember only three things, make them these: no documented link between the two, Kraft Heinz is now led by Steve Cahillane, and any precise net worth for either man should be treated with suspicion.
FAQ’s
Are Miguel Patricio and Albert Bourla related?
No public record shows any family relationship between them.
Are Miguel Patricio and Albert Bourla business partners?
No. Patricio worked at Kraft Heinz and AB InBev, while Bourla works at Pfizer. Patricio is not among Pfizer’s 2026 director nominees.
Who is Miguel Patricio?
He is a Portuguese executive who led marketing at AB InBev, served as Kraft Heinz CEO from July 2019 and later as its Chair and Executive Chair, and is listed on the AB InBev board.
Who is Albert Bourla?
He is a Greek-born, U.S. citizen veterinarian turned pharmaceutical executive who has been Pfizer’s CEO since January 2019 and Chairman since January 2020.
Is Miguel Patricio still CEO of Kraft Heinz?
No. He stepped down as CEO at the end of 2023 and later retired as Executive Chair.
Who is the current CEO of Kraft Heinz?
Steve Cahillane, who took over on January 1, 2026.
Is Albert Bourla still CEO of Pfizer?
Yes. Pfizer’s 2026 proxy statement and recent company communications identify him as Chairman and CEO.
How old is Albert Bourla?
He turned 65 on October 21, 2026.
How old is Miguel Patricio?
His exact birthdate is not public. Sources point to about 60.
How much does Albert Bourla earn?
Pfizer reported total 2025 compensation of $27,585,301 for him, up from $24,648,727 in 2024.
What is Miguel Patricio’s or Albert Bourla’s net worth?
No filing reports a net worth for either man. Online estimates range from about $15 million to $150 million for Bourla and are unsourced. A data provider estimates Patricio’s Kraft Heinz shares at about $30 million, which is one holding, not a net worth.
What was Albert Bourla’s first job at Pfizer?
He joined in 1993 as Technical Director of Greece in the animal health division.
